Sonnet’s key strengths lie in its innovative FHAB platform, which offers a clear scientific rationale for improving cytokine therapies, and in a diversified early‑stage pipeline built on that platform. The company maintains very low traditional debt, reducing the risk of creditor pressure, and has recently strengthened its liquidity position through equity financing and a business combination that added a digital‑asset treasury. Cost controls have moderated the rate of losses and cash burn, and early clinical signals from SON‑1010 provide some initial, though limited, validation of the approach. A meaningful patent runway underpins its technology and could support long‑term value if programs succeed.

Major risks include persistent and sizable operating losses, a negligible revenue base, and a long history of shareholder dilution, as reflected in multiple reverse stock splits. The business remains heavily dependent on equity markets and on the value and liquidity of its crypto holdings to fund ongoing trials. Scientific and regulatory risks are high: failure in key trials or safety issues could significantly impair the pipeline. Competitive pressures from much larger immuno‑oncology players, coupled with leadership transition and the complexity of integrating a digital‑asset‑heavy corporate structure, add further uncertainty.

Looking ahead, Sonnet’s trajectory is likely to remain binary and event‑driven, typical of early‑stage biotech. Financial metrics are unlikely to improve meaningfully without clear clinical wins, partnering deals, or eventual product approvals. Near‑term focus will revolve around delivering robust data from SON‑1010, advancing SON‑1210 and IL‑18 candidates, and carefully managing cash in a volatile funding environment. If the platform continues to generate encouraging data and the company effectively leverages its new capital structure, Sonnet could evolve from a purely development‑stage story toward a more sustainable model; if not, pressure on the balance sheet and equity could resurface over time.